6 news items
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
VIR
13 May 24
Organization. (AprilĀ 2024). Global hepatitis report 2024: action for access in low- and middle-income
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
VIR
11 Apr 24
.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
will receive an email with important details for this call, including the call date, time and access link. This link is to be kept confidential
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
; challenges in accessing manufacturing capacity; clinical site activation rates or clinical trial enrollment rates that are lower than expected; difficulties
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
VIR
23 Feb 24
.
Live webcasts of the fireside chats can be accessed under Events & Presentations in the Investors section
o5k2t657ujrgaivzm3ocbipn0auuonh49dl2webco4ac t5oy
VIR
22 Feb 24
companies can be achieved; difficulties in collaborating with other companies; challenges in accessing manufacturing capacity; clinical site activation rates
- Prev
- 1
- Next